Back to Research

Organization profile

Altamira Therapeutics

Altamira Therapeutics is a clinical-stage biopharmaceutical organization focused on developing peptide-based nanoparticle technologies for the extrahepatic delivery of RNA therapeutics. The company utilizes its proprietary xPhore and CycloPhore platforms to target indications such as KRAS-driven cancer and rheumatoid arthritis while divesting legacy assets in consumer health and CNS.

Basel, SwitzerlandFounded 2003

Overview

1. Executive Summary (Confidence: High)

Altamira Therapeutics is currently undergoing a radical strategic repositioning, shifting its focus from legacy clinical development in inner ear and allergic rhinitis to becoming a "leading provider of innovative RNA delivery technology". The organization’s value proposition is built upon its proprietary "xPhore" platform (encompassing OligoPhore and SemaPhore), which utilizes a patented peptide to deliver siRNA and mRNA to extrahepatic tissues—a major bottleneck in the RNA industry. Despite a turbulent 2024–2025 marked by a transition from Nasdaq to the OTCQB marketplace and a critically low cash position (reporting only $4,000 as of June 2025), Altamira continues to advance its flagship AM-401 program toward an IND submission. Its "picks and shovels" strategy involves out-licensing its platform to biopharma partners and spinning off its RNA delivery business into a separate subsidiary (ATAG) to attract private equity funding.

Unlock the full profileGet the complete company dossier

This public view only shows an extract. Open the full profile to access the complete company intelligence record, including the full write-up and structured research details.

Desktop only

Research is currently available on desktop only.

The Research module is designed for larger screens. Please reopen it on a desktop or laptop to use the screener, filters, detail pages, and admin tools.